2020 WGND Virtual Annual Meeting

October 19, 2020 | Zoom Webinar

Overview

The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in research and development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.

Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Zaid Tanvir
TB Alliance, WGND
Andrew Nunn
Clinical Trials Unit, MRC
Gavin Churchyard
AIDS Clinical Trials Group
June Kim
Julia Dreisbach
Norbert Heinrich
University of Munich
Tine DeMarez
Janssen
Robert Bates
Charles Wells
Gates Medical Research Institute
Steve Berthel
Francesca Conradie
Nicholas Paton
Andrew Vernon
TB Trials Consortium (CDC)
Morounfolu Olugbosi
TB Alliance
Marc Destito
Otsuka
Brendan Crowley
Daniel Frank
NIAID, NIH
Thomas Manning
Robert Wallis
The Aurum Institute
Meeting Recap

The 2020 WGND Annual Meeting took place on Monday, October 19th at 9AM -12PM EDT. During the meeting, updates were provided by representatives from pharmaceutical, government agencies, research organizations, non-profits, academia, and others involved in TB research and development. 

Presentations and Q&A from the meeting will be posted within 7-10 days from the meeting date.

  • TB Drug Development Year-in-Review
    Barbara Laughon
    https://www.newtbdrugs.org/sites/default/files/meetings/files/01_Barbara%20Laughon_Year-in-Review.pdf
    WGND Updates
    Zaid Tanvir
    https://www.newtbdrugs.org/sites/default/files/meetings/files/02_Zaid%20Tanvir_WGND%20Update.pdf
    STREAM2
    Andrew Nunn
    https://www.newtbdrugs.org/sites/default/files/meetings/files/03__Andrew%20Nunn_STREAM.pdf
    AIDS Clinical Trials Group
    Gavin Churchyard
    https://www.newtbdrugs.org/sites/default/files/meetings/files/04_Gavin%20Churchyard_ACTG.pdf
    Qurient, Inc.
    June Kim
    https://www.newtbdrugs.org/sites/default/files/meetings/files/05_June%20Kim_Qurient_Telacebec_.pdf
    University of Munich / PanACEA
    Norbert Heinrich
    Julia Dreisbach
    https://www.newtbdrugs.org/sites/default/files/meetings/files/06_Julia%20Dreisbach%20%26%20Norbert%20Heinrich_PanACEA%20LMU.pdf
    Janssen
    Tine DeMarez
    https://www.newtbdrugs.org/sites/default/files/meetings/files/07_Tine%20De%20Marez_Janssen.pdf
    GlaxoSmithKline
    Robert Bates
    https://www.newtbdrugs.org/sites/default/files/meetings/files/08_Rob%20Bates_GSK.pdf
    BEAT Tuberculosis
    Francesca Conradie
    https://www.newtbdrugs.org/sites/default/files/meetings/files/11_Francesca%20Conradie_BEAT%20TB.pdf
    TB Drug Accelerator
    Steve Berthel
    https://www.newtbdrugs.org/sites/default/files/meetings/files/10_Steve%20Berthel_TBDA.pdf
    Gates Medical Research Institute
    Charles Wells
    https://www.newtbdrugs.org/sites/default/files/meetings/files/09_Charles%20Wells_GMRI.pdf
    SPRINT-TB
    Nicholas Paton
    https://www.newtbdrugs.org/sites/default/files/meetings/files/12_Nick%20Paton_TRUNCATE-TB.pdf
    Centers for Disease Control/ TB Trials Consortium
    Andrew Vernon
    TB Alliance
    Morounfolu Olugbosi
    https://www.newtbdrugs.org/sites/default/files/meetings/files/14_Folu%20Olugbosi_TB%20Alliance.pdf
    Otsuka
    Marc Destito
    https://www.newtbdrugs.org/sites/default/files/meetings/files/15_Marc%20Destito_Otsuka.pdf
    Merck
    Brendan Crowley
    DAIDS/NIAID, NIH
    Daniel Frank
    https://www.newtbdrugs.org/sites/default/files/meetings/files/17_Daniel%20Frank_DAIDS_NIAID_NIH.pdf
    Valdosta State University
    Thomas Manning
    https://www.newtbdrugs.org/sites/default/files/meetings/files/18_Thomas%20Manning_Valdosta%20University.pdf
    Aurum Institute
    Robert Wallis
    https://www.newtbdrugs.org/sites/default/files/meetings/files/19_Bob%20Wallis_Aurum.pdf
Downloads